Osteologix, Inc. (OLGX.OB)


Osteologix is developing NB S101, a once daily tablet containing strontium malonate, as a treatment for osteoporosis. The phase II study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial with the objective of assessing the effects of NB S101 on bone metabolism while also evaluating its safety, tolerability and pharmacokinetics in postmenopausal women. In addition to the primary endpoint of bone resorption, the company is evaluating the effects of NB S101 on bone formation and bone mineral density.

Contact Information

425 Market Street
Suite 2230
San Francisco, CA 94105

tel: 415-955-2726
fax: 415-955-2727


Investor Relations



Exchange: OTCBB
Industry: Diagnostic Substances
Market Cap: $24.7M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.